Blog

Technology is transforming how specialty pharmacies deliver care to patients with complex and rare diseases, especially when leveraging advanced case coordination tools. This research highlights a Claritas Rx study evaluating the impact of CRM-driven, real-time collaboration across specialty pharmacy networks on patient fill rates and the time taken to initiate therapy—key metrics for quality, efficiency, […]

Claritas Rx is excited to share our feature on the National Association of Specialty Pharmacy (NASP) podcast, where our Director of Data Strategy Hillary Gretton dives deep into how Access Analytics is transforming the specialty pharmaceutical space and patient care. What You’ll Learn from the Podcast In this insightful episode, “Turning Data into Action –

Author: Meghna Misra, Head of Product at Claritas Rx In the rapidly evolving life sciences industry, the complexities of the U.S. healthcare system create significant challenges for market access, analytics, and patient outcomes. Central to overcoming these challenges is payer mastering, an advanced capability that, when applied strategically, enables organizations to move beyond incremental progress

Commercializing a therapy for rare diseases is a challenging endeavor. With the complexities of patient access, regulatory hurdles, and stakeholder engagement, manufacturers must adopt a carefully crafted strategic framework. In a recent Access USA panel discussion, industry experts shared their valuable perspectives on this topic. The panel featured Justin Bush from Pharavis, Richard Wilson from

Specialty pharmacies (SPs) play a crucial role in delivering complex medications to patients who require ongoing support throughout their treatment journeys. However, the effectiveness of SPs often hinges on timely intervention, efficiency, and seamless collaboration among stakeholders. These challenges are further amplified by time-consuming manual processes, delayed responses, and lack of real-time visibility into patient

Guiding patients through their treatment journey is a critical yet intricate task for patient services teams. One of the biggest obstacles they face is “patient drop-off,” the moments when individuals disengage or discontinue treatment. These drop-offs can significantly impact healthcare outcomes, operational efficiency, and access to care. This blog explores the key stages in the

Macular telangiectasia (MacTel) type 2, a rare neurodegenerative eye condition, has long left many without access to effective treatment. This disease silently affects central vision, making everyday tasks like reading and recognizing faces increasingly challenging for those impacted. However, patients and biopharma professionals alike have reason to look ahead with renewed optimism. On March 6,

Every year, millions of people around the world come together to show support and amplify the voices of those living with rare diseases. Rare Disease Day, observed on February 28 (or 29th on leap years), is a vital opportunity to increase public awareness and understanding of rare diseases, their impact, and the need for more

The treatment landscape for rare diseases is rapidly evolving, offering both opportunities and challenges for biopharma professionals and patient service teams. With over 7,000 known rare diseases affecting an estimated 300 million people globally, the need for innovation and collaboration has never been greater. Yet, rare diseases are often underfunded, understudied, and misunderstood, leaving many

Rare diseases affect approximately 30 million people in the United States, yet the path to diagnosing and treating these conditions remains notoriously complex. With small patient populations, high treatment costs, and the necessity for robust engagement strategies, the rare disease sector is filled with challenges. For biopharma professionals, the focus remains on finding innovative ways